The FASEB Journal, Vol 11, 753-763, Copyright © 1997 by The Federation of American Societies for Experimental Biology

REVIEWS

Genetic immunization: a new era in vaccines and immune therapeutics

M Chattergoon, J Boyer and DB Weiner
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104, USA.

DNA inoculation represents a novel approach to vaccine and immune therapeutic development. The direct injection of gene expression cassettes into a living host transforms a number of cells into factories for production of the introduced gene products. Expression of these delivered genes has important immunological consequences and may result in the specific immune activation of the host against the novel expressed antigens. The recent demonstration by laboratories that these immune responses are protective in some infectious disease experimental models as well as cancers is viewed with cautious optimism. Further, the relatively short development times, ease of large-scale production, low development, manufacturing, and distribution costs all combine with immunological effectiveness to suggest that this technology will dramatically influence the production of a new generation of experimental vaccines and immune therapies. It is hoped that DNA inoculation will ultimately lead to new vaccines that are immunologically effective and economically accessible to all nations.

This article has been cited by other articles:

				M. Rosati, A. von Gegerfelt, P. Roth, C. Alicea, A. Valentin, M. Robert-Guroff, D. Venzon, D. C. Montefiori, P. Markham, B. K. Felber, et al. DNA Vaccines Expressing Different Forms of Simian Immunodeficiency Virus Antigens Decrease Viremia upon SIVmac251 Challenge J. Virol., July 1, 2005; 79(13): 8480 - 8492. [Abstract] [Full Text] [PDF]

				R. Xiang, N. Mizutani, Y. Luo, C. Chiodoni, H. Zhou, M. Mizutani, Y. Ba, J. C. Becker, and R. A. Reisfeld A DNA Vaccine Targeting Survivin Combines Apoptosis with Suppression of Angiogenesis in Lung Tumor Eradication Cancer Res., January 15, 2005; 65(2): 553 - 561. [Abstract] [Full Text] [PDF]

				M. Giri, K. E. Ugen, and D. B. Weiner DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade Clin. Microbiol. Rev., April 1, 2004; 17(2): 370 - 389. [Abstract] [Full Text] [PDF]

				P. W. Zoltick, N. Chirmule, M. A. Schnell, G.-P. Gao, J. V. Hughes, and J. M. Wilson Biology of E1-Deleted Adenovirus Vectors in Nonhuman Primate Muscle J. Virol., June 1, 2001; 75(11): 5222 - 5229. [Abstract] [Full Text]

				Z. Li, A. Howard, C. Kelley, G. Delogu, F. Collins, and S. Morris Immunogenicity of DNA Vaccines Expressing Tuberculosis Proteins Fused to Tissue Plasminogen Activator Signal Sequences Infect. Immun., September 1, 1999; 67(9): 4780 - 4786. [Abstract] [Full Text] [PDF]

				G. Milan, A. Zambon, M. Cavinato, P. Zanovello, A. Rosato, and D. Collavo Dissecting the Immune Response to Moloney Murine Sarcoma/Leukemia Virus-Induced Tumors by Means of a DNA Vaccination Approach J. Virol., March 1, 1999; 73(3): 2280 - 2287. [Abstract] [Full Text]

				Adam. D. Cohen, J. D. Boyer, and D. B. Weiner Modulating the immune response to genetic immunization FASEB J, December 1, 1998; 12(15): 1611 - 1626. [Abstract] [Full Text]